Clinical Research Directory

Congenital Athymia Patient Registry

Sponsor: Sumitomo Pharma Switzerland GmbH

Summary

This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).

Official title: Congenital Athymia Patient Registry of RETHYMIC

Key Details

Conditions

Interventions

Locations (1)